Clinical trial NCT01060423 (phase 2, status: terminated)
Conditions: colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: cetuximab, irinotecan
SMILES: [H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O, CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=CC=CC=C4N=C13)C2=O
Reason stopped: 
    terminated due to poor subject enrolment
  
Eligibility criteria:

        Inclusion Criteria:

          1. Patients with confirmed diagnosis of stage IV (UICC) colorectal cancer with
             unresectable liver metastases (primary tumour may be present) and k-ras wild-type
             tumours

          2. Patients had been treated and shown to be refractory to 5-FU (Capecitabine
             allowed)/oxaliplatin and/or 5-FU/irinotecan. Prior therapy with VEGF-inhibitors (e.g
             bevacizumab) is allowed

          3. Patients with at least one measurable liver metastasis, with size > 1cm (RECIST
             criteria)

          4. Patients with liver only or liver dominant disease (defined as ≥ 50 % tumour burden
             confined to the liver)

          5. Patients with a portal vein not interfering with transarterial chemoembolization (e.g.
             no thrombosis) as judged by the investigator

          6. ECOG Performance status ≤ 2

          7. Life expectancy > 3 months

          8. Age ≥ 18 years.

          9. At least 4 weeks since last administration of last chemotherapy and/or radiotherapy
             (bone metastases may be allowed)

         10. Patients who received VEGF-inhibition (e.g. with bevacizumab) in prior therapy are
             eligible if stopped since 4-6 weeks before randomization

         11. Haematologic function: ANC ≥ 1.5 x 109/L, platelets ≥ 75 x109/L

         12. INR < 1.5 (patients on therapeutic anticoagulants are not eligible)

         13. Adequate liver function as measured by serum transaminases (AST & ALT) ≤ 3 x ULN and
             total bilirubin ≤ 1.5 x ULN

         14. Adequate renal function: Serum creatinine ≤ 1.5 x ULN

         15. Normal level of serum magnesium

         16. Women of child bearing potential and fertile men are required to use effective
             contraception (negative serum βHCG for women of child-bearing age

         17. Signed, written informed consent

        Exclusion Criteria:

          1. Presence of CNS metastases

          2. Contraindications to irinotecan therapy (Chronic inflammatory bowel disease and/or
             bowel obstruction, history of severe hypersensitivity reactions to irinotecan
             hydrochloride trihydrate)

          3. Active bacterial, viral or fungal infection within 72 hours of study entry

          4. Women who are pregnant or breast feeding

          5. Allergy to contrast media

          6. Presence of another concurrent malignancy. Prior malignancy in the last 5 years except
             adequately treated basal or squamous cell skin cancer or carcinoma in situ of the
             cervix

          7. Any contraindication for hepatic embolisation procedures:

               -  Large shunt as determined by the investigator (pretesting with lung perfusion
                  scan not required)

               -  Severe atheromatosis

               -  Hepatofugal blood flow

          8. Other significant medical or surgical condition, or any medication or treatment, that
             would place the patient at undue risk, that would preclude the safe use of
             chemoembolization or would interfere with study participation

          9. Known hypersensitivity or contraindication to the drugs used in the trial (eg:
             cetuximab, 5-HT3 receptor antagonist, dexamethasone, or any component of aprepitant)